RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employeesAug 21, 2023 - Gilead Sciences revealed its CD47 molecule has been placed under a partial clinical hold by the FDA for its phase 3 acute myeloid leukemia (AML) studies.
The news comes a month to the day after Gilead revealed it had canned studies in MDS for the CD47 asset, which was acquired along with Forty Seven for $4.9 billion. Gilead shut the late-stage study down for futility after getting a look at phase 3 data.
https://www.fiercebiotech.com/biotech/gileads-magrolimab-once-again-placed-partial-clinical-hold-another-setback-forty-seven-bet